icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen
 
 
  EASL 2022 June 22-26 London
 
Edward J. Gane1, Bridget Faire2, Sherine Helmy3, James Freeman4. 1University of Auckland, Grafton Campus, Liver Unit, Auckland, New Zealand; 2New Zealand Liver Transplant Unit-Ward 71, Auckland, New Zealand; 3Pharco Corporation, Cairo, Egypt; 4GP2U, Australia

0626221

0626222

0626223

0626224

0626225

0626226

0626227

0626228

0626229

06262210

06262211

06262212